Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Turalio (pexidartinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo

Drug class:

c-KIT inhibitor, FLT3 inhibitor, AKT inhibitor, CSF-1R inhibitor, FMS kinase inhibitor

Related drugs:

‹

axatilimab-csfr (0)

dasatinib (215)

sunitinib (139)

lenvatinib (90)

ripretinib (11)

BAY 57- 9352 (0)

quizartinib (40)

flonoltinib (0)

capivasertib (37)

enzastaurin (3)

antroquinonol (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

avapritinib (13)

axatilimab-csfr (0)

›

No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	pexidartinib Sensitive: C4 – Case Studies pexidartinib Sensitive : C4	pexidartinib Sensitive: C4 – Case Studies pexidartinib Sensitive : C4
CCND3 T283A	Acute Myelogenous Leukemia	CCND3 T283A	Acute Myelogenous Leukemia	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4
CCND3 Q276* + CCND3 S264R	Acute Myelogenous Leukemia	CCND3 Q276* + CCND3 S264R	Acute Myelogenous Leukemia	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	pexidartinib Sensitive: D – Preclinical pexidartinib Sensitive : D	pexidartinib Sensitive: D – Preclinical pexidartinib Sensitive : D